The diagnostic value of soluble urokinase plasminogen activator receptor in crimean-congo hemorrhagic fever disease in the emergency department Acil serviste kırım kongo kanamalı ateş hastalığında soluble ürokinaz plazminojen aktivatör reseptörünün tanısal değeri

Creative Commons License

Küçükceran K., Karaşahin Ö., Delice O., BATUR A., İba Yilmaz S., Şebin E., ...More

Duzce Medical Journal, vol.23, no.1, pp.15-19, 2021 (Scopus) identifier

  • Publication Type: Article / Article
  • Volume: 23 Issue: 1
  • Publication Date: 2021
  • Doi Number: 10.18678/dtfd.820602
  • Journal Name: Duzce Medical Journal
  • Journal Indexes: Scopus, Academic Search Premier, CINAHL, EMBASE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.15-19
  • Keywords: Crimean-Congo, Diagnosis, Hemorrhagic fever virus, Receptors, Urokinase plasminogen activator
  • Hacettepe University Affiliated: Yes


Aim: The urokinase-type plasminogen activator (uPA) system consists of a protease, a receptor (urokinase-type plasminogen activator receptor, uPAR), and inhibitors that can be expressed on various cell types. Previous literature shows that the amount of soluble urokinase-type plasminogen activator receptor (suPAR) secreted from affected cells is higher in Crimean-Congo hemorrhagic fever (CCHF) patients than in healthy controls. Thus, we aimed to investigate the diagnostic value of suPAR in the differential diagnosis of CCHF in emergency services. Material and Methods: Individuals over 16 years old with a preliminary diagnosis of CCHF disease were divided into two groups as real time-polymerase chain reaction (RT-PCR) and/or IgM positive (CCHF group) and RT-PCR and/or IgM negative (control group). Results: Eighty patients were included in this study. Forty patients with CCHF virus PCR and/or CCHF virus IgM were identified as CCHF group and 40 patients included as negative control group. The median age of the patients was 45 (range, 16-91) years, and 49 patients (61.3%) were male. Leukocyte, platelet, and fibrinogen levels were significantly lower, while creatinine kinase, aPTT, and D-dimer levels were significantly higher in CCHF group. There was no statistically significant difference between the control group and CCHF group for SuPAR (p=0.386). In addition, control group patients not diagnosed with CCHF were examined, brucellosis, influenza, and pneumonia were found to be the most common. Conclusion: The use of suPAR as a biomarker in the differentiation of patients with similar findings in emergency services was investigated and found to have no diagnostic value.